JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

A Salas, C Hernandez-Rocha, M Duijvestein… - Nature reviews …, 2020 - nature.com
Cytokines are involved in intestinal homeostasis and pathological processes associated
with inflammatory bowel disease (IBD). The biological effects of cytokines, including several …

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata

M Lensing, A Jabbari - Frontiers in immunology, 2022 - frontiersin.org
Alopecia Areata (AA) is a common autoimmune disease characterized by non-scarring hair
loss ranging from patches on the scalp to complete hair loss involving the entire body …

Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165

ST Wrobleski, R Moslin, S Lin, Y Zhang… - Journal of Medicinal …, 2019 - ACS Publications
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in
treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that …

STING controls nociception via type I interferon signalling in sensory neurons

CR Donnelly, C Jiang, AS Andriessen, K Wang… - Nature, 2021 - nature.com
The innate immune regulator STING is a critical sensor of self-and pathogen-derived DNA.
DNA sensing by STING leads to the induction of type-I interferons (IFN-I) and other …

Vitiligo: mechanisms of pathogenesis and treatment

ML Frisoli, K Essien, JE Harris - Annual review of immunology, 2020 - annualreviews.org
Vitiligo is an autoimmune disease of the skin that targets pigment-producing melanocytes
and results in patches of depigmentation that are visible as white spots. Recent research …

[HTML][HTML] A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia …

B King, E Guttman-Yassky, E Peeva, A Banerjee… - Journal of the American …, 2021 - Elsevier
Background Alopecia areata (AA) is an autoimmune form of hair loss with limited treatments.
Objective To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and …

MONN: a multi-objective neural network for predicting compound-protein interactions and affinities

S Li, F Wan, H Shu, T Jiang, D Zhao, J Zeng - Cell Systems, 2020 - cell.com
Computational approaches for understanding compound-protein interactions (CPIs) can
greatly facilitate drug development. Recently, a number of deep-learning-based methods …

Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention

GW Sewell, A Kaser - Journal of Crohn's and Colitis, 2022 - academic.oup.com
Abstract The interleukin-23 [IL-23] cytokine, derived predominantly from macrophages and
dendritic cells in response to microbial stimulation, has emerged as a critical promoter of …

[HTML][HTML] Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis

JG Krueger, IB McInnes, A Blauvelt - Journal of the American Academy of …, 2022 - Elsevier
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease.
The Janus kinase-signal transducer and activator of transcription pathway plays a major role …

[HTML][HTML] Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study

WJ Sandborn, S Danese, J Leszczyszyn… - Clinical …, 2023 - Elsevier
Background & Aims The efficacy and safety of ritlecitinib (oral JAK3/TEC family kinase
inhibitor) and brepocitinib (oral TYK2/JAK1 inhibitor) as induction therapy were assessed in …